"Trade Margin Rationalisation is a more market-friendly alternative to ceiling prices for controlling drug costs." Critically examine this with reference to anti-cancer medicines in India.

India sets drug prices under the Drugs (Prices Control) Order, 2013 (DPCO 2013). NPPA fixes ceiling prices for medicines on the NLEM (Schedule-I). For all other (non-scheduled) drugs, the only rule is that MRP cannot rise by more than 10% a year [1]. Trade Margin Rationalisation (TMR) works differently. It caps only the supply-chain mark-up, which since October 2026 is 30% of MRP for all non-scheduled anti-cancer drugs [2]. TMR is a lighter tool than ceiling prices, but it has clear gaps.

Why TMR is more market-friendly

• Manufacturer's price stays free: only distributor and retailer margins are capped, so companies keep the incentive to launch and import new drugs [2].
• Targets the real distortion: NPPA found an average mark-up of about 170%, and over 700% in some cases. The excess lies in the trade chain, not in production [2].
• Proven results: the 2019 pilot under Para 19 covered 42 drugs. It cut the MRPs of 526 brands by about 50% and saves patients about ₹984 crore a year [3].
• Wide reach without NLEM listing: the cap covers branded, generic, patented and imported drugs. Prices are expected to fall by up to 70%, saving patients ₹2,500 crore a year [2].
• Endorsed by Parliament: the Standing Committee called TMR "a viable means of controlling drug prices" [4].

Limitations

• Weak legal footing: DPCO allows margin capping only temporarily [4], and there is still no permanent TMR framework [5].
• Base price unchecked: for patented imported drugs, the manufacturer's price is the main cost. Companies can still raise it by up to 10% a year [1].
• Opaque margins: the price-to-stockist (PTS) price is not made public, so patients cannot check whether the cap is followed [4].
• Enforcement gaps: NPPA lacks hospital and rural sales data, and overcharged amounts remain unrecovered because of litigation [5]. Online pharmacies have no pricing rules [4].
• Flat-rate design: 30% of a ₹1 lakh injection is still ₹30,000. Also, the supply safeguard binds only manufacturers, who must keep production at current levels [2]. Nothing obliges chemists to keep stocking low-volume cancer drugs.

TMR is a calibrated middle path. It removes profiteering in the trade chain without fixing producers' prices, so it complements ceiling prices rather than replacing them. The way forward is to:

• amend DPCO to give TMR a permanent legal basis [4];
• publish PTS data;
• extend monitoring to hospital and rural markets [5];
• move towards graded, transparent mark-up rules of the kind WHO advises for the whole supply chain [6].

Together, these steps would turn a pilot into durable policy that advances Universal Health Coverage (SDG 3.8) and the duty to improve public health under Article 47.